Dr. Mathai Mammen

Senior Advisor

REGION United States


Mathai Mammen, M.D., Ph.D., is a Senior Advisor at General Atlantic. In his role, Dr. Mammen provides strategic counsel and advises the firm’s Life Sciences investment team and portfolio companies.

Dr. Mammen brings more than 25 years of leadership experience in the biopharmaceutical industry, focusing on drug discovery, development and scaling of small and large businesses. He currently serves as Chairman, President and Chief Executive Officer of FogPharma, a biopharmaceutical company developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability.

Before assuming his role at FogPharma in 2023, Dr. Mammen had a critical role in leading Johnson & Johnson’s expansion in COVID vaccines as Executive Vice President of Pharmaceuticals, R&D, and also served on the Executive Committee. He is also credited for spearheading initiatives and strategies at Janssen’s R&D that propelled the company to global recognition as one of the largest R&D organizations and one of the leading pharmaceutical companies in the world. Dr. Mammen held previous R&D roles at Merck, Inc. and Theravance, a company he co-founded in 1997 following his studies and research at Harvard University.

Current Board Affiliations

10x Genomics, Inc, Board Member


Dalhousie University, B.S., Chemistry
Harvard Medical School and Massachusetts Institute of Technology HST program, M.D.
Harvard University, Ph.D., Chemistry

Senior Advisors are independent contractors that are advisors to General Atlantic and its portfolio companies. They are not employees nor affiliates of General Atlantic entities.

Advisory Directors are former Managing Directors who have retired under General Atlantic’s retirement policy.